Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent

Jimeno-Sánchez, Javier; Fuertes-Ferre, Georgina; Ruiz-Aranjuelo, Alejandra; Caballero-Jambrina, Isabel; Miguel, José A. Diarte-de; Ortas-Nadal, Maria Rosario

doi:10.24875/acme.m20000067

Cited by 2 publications

(1 citation statement)

References 21 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports have shown a gender difference in treatment choice of P2Y12 inhibitors [20,21]. This was also demonstrated in the present study, where less than 28% of patients receiving ticagrelor and less than 20% of those receiving prasugrel were female.…”

Section: Discussionsupporting

confidence: 85%

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017

Rezaei

Gleiß

Reichardt³

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Dual antiplatelet therapy improves patient outcome after acute coronary syndrome (ACS), but prescription differences of P2Y12 inhibitor treatments exist. The aim of the present investigation was to study the long-term utilization and patient outcomes of clopidogrel, prasugrel, and ticagrelor in patients with ACS from 2015 to 2017 in Austria. Methods: Data from 13 Austrian health insurance funds of patients with a hospital discharge diagnosis of ACS for the years 2015 to 2017 were analyzed. The primary end point was to investigate the recurrence of ACS or death. Results: Of 49,124 P2Y12 inhibitor-naive patients with a hospital discharge diagnosis of ACS, 25,147 subjects filled a P2Y12 inhibitor prescription within 30 days after the index event. Of these patients, 10,626 (42.9%) subjects had a prescription for clopidogrel, 4788 (19.3%) for prasugrel, and 9383 (37.8%) for ticagrelor. Ticagrelor was the most frequently prescribed P2Y12 inhibitor among patients below 70 years old, and clopidogrel in those aged ≥70 years. Occurrence of an endpoint was highest in elderly patients. After adjustment for age, sex, and pre-existing medication as proxy for comorbidity, the hazard ratio for ACS or death for prasugrel vs. clopidogrel of 0.70 (95% CI: 0.61; 0.79) was similar to that of ticagrelor vs. clopidogrel (0.70; 95% CI: 0.64; 0.77). Conclusion: Prescription of ticagrelor or prasugrel after ACS were associated with a lower risk of ACS recurrence or death compared to clopidogrel.

show abstract

Section: Discussionsupporting

confidence: 85%

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017

Rezaei

Gleiß

Reichardt³

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes

Occhipinti

Greco

Angiolillo

et al. 2023

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent

Abstract: Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent Diferencias en el tratamiento antitrombótico y pronóstico en función del sexo en pacientes con síndrome coronario agudo tratados con stent

Cited by 2 publications

References 21 publications

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017

Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes

Contact Info

Product

Resources

About